A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta

Linda DiMeglio, L. Ford, C. McClintock, Munro Peacock

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been established. This report is an analysis of an open-label, prospective, randomized clinical trial of oral compared to intravenous bisphosphonate medications in children with osteogenesis imperfecta. Children were stratified according to bone age, pubertal stage, and type of osteogenesis imperfecta and then randomized to receive intravenous pamidronate, 3 mg/kg over 3 days every 4 months, or oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily. The primary efficacy outcome was change in bone mineral density. Secondary outcomes included change in biomarkers of bone turnover, fracture incidence, and growth rate. Ten children were randomized (6 oral and 4 intravenous). Two other children were assigned to intravenous treatment due to chronic abdominal pain. In each group, three patients had type III/IV osteogenesis imperfecta, while three had type I. All 12 children completed 8 months of therapy; nine completed 12 months. Bone mineral density increased in both oral and intravenous groups equally and beyond that expected with normal growth. All children had a decrease in biochemical markers of bone turnover. Linear growth showed a moderate increase above that for age. There was a non-significant decrease in fracture incidence in both groups.

Original languageEnglish
Pages (from-to)43-53
Number of pages11
JournalJournal of Pediatric Endocrinology and Metabolism
Volume18
Issue number1
StatePublished - Jan 2005

Fingerprint

Osteogenesis Imperfecta
Diphosphonates
Bone Density
pamidronate
Bone Remodeling
Bone Fractures
Therapeutics
Growth
Biomarkers
Alendronate
Incidence
Chronic Pain
Abdominal Pain
Randomized Controlled Trials
Bone and Bones

Keywords

  • Bisphosphonate
  • Children
  • Fracture
  • Osteogenesis imperfecta
  • Pediatrics

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. / DiMeglio, Linda; Ford, L.; McClintock, C.; Peacock, Munro.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 18, No. 1, 01.2005, p. 43-53.

Research output: Contribution to journalArticle

@article{e0ec15da46d04bfabf72346edfa879db,
title = "A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta",
abstract = "Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been established. This report is an analysis of an open-label, prospective, randomized clinical trial of oral compared to intravenous bisphosphonate medications in children with osteogenesis imperfecta. Children were stratified according to bone age, pubertal stage, and type of osteogenesis imperfecta and then randomized to receive intravenous pamidronate, 3 mg/kg over 3 days every 4 months, or oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily. The primary efficacy outcome was change in bone mineral density. Secondary outcomes included change in biomarkers of bone turnover, fracture incidence, and growth rate. Ten children were randomized (6 oral and 4 intravenous). Two other children were assigned to intravenous treatment due to chronic abdominal pain. In each group, three patients had type III/IV osteogenesis imperfecta, while three had type I. All 12 children completed 8 months of therapy; nine completed 12 months. Bone mineral density increased in both oral and intravenous groups equally and beyond that expected with normal growth. All children had a decrease in biochemical markers of bone turnover. Linear growth showed a moderate increase above that for age. There was a non-significant decrease in fracture incidence in both groups.",
keywords = "Bisphosphonate, Children, Fracture, Osteogenesis imperfecta, Pediatrics",
author = "Linda DiMeglio and L. Ford and C. McClintock and Munro Peacock",
year = "2005",
month = "1",
language = "English",
volume = "18",
pages = "43--53",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta

AU - DiMeglio, Linda

AU - Ford, L.

AU - McClintock, C.

AU - Peacock, Munro

PY - 2005/1

Y1 - 2005/1

N2 - Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been established. This report is an analysis of an open-label, prospective, randomized clinical trial of oral compared to intravenous bisphosphonate medications in children with osteogenesis imperfecta. Children were stratified according to bone age, pubertal stage, and type of osteogenesis imperfecta and then randomized to receive intravenous pamidronate, 3 mg/kg over 3 days every 4 months, or oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily. The primary efficacy outcome was change in bone mineral density. Secondary outcomes included change in biomarkers of bone turnover, fracture incidence, and growth rate. Ten children were randomized (6 oral and 4 intravenous). Two other children were assigned to intravenous treatment due to chronic abdominal pain. In each group, three patients had type III/IV osteogenesis imperfecta, while three had type I. All 12 children completed 8 months of therapy; nine completed 12 months. Bone mineral density increased in both oral and intravenous groups equally and beyond that expected with normal growth. All children had a decrease in biochemical markers of bone turnover. Linear growth showed a moderate increase above that for age. There was a non-significant decrease in fracture incidence in both groups.

AB - Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been established. This report is an analysis of an open-label, prospective, randomized clinical trial of oral compared to intravenous bisphosphonate medications in children with osteogenesis imperfecta. Children were stratified according to bone age, pubertal stage, and type of osteogenesis imperfecta and then randomized to receive intravenous pamidronate, 3 mg/kg over 3 days every 4 months, or oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily. The primary efficacy outcome was change in bone mineral density. Secondary outcomes included change in biomarkers of bone turnover, fracture incidence, and growth rate. Ten children were randomized (6 oral and 4 intravenous). Two other children were assigned to intravenous treatment due to chronic abdominal pain. In each group, three patients had type III/IV osteogenesis imperfecta, while three had type I. All 12 children completed 8 months of therapy; nine completed 12 months. Bone mineral density increased in both oral and intravenous groups equally and beyond that expected with normal growth. All children had a decrease in biochemical markers of bone turnover. Linear growth showed a moderate increase above that for age. There was a non-significant decrease in fracture incidence in both groups.

KW - Bisphosphonate

KW - Children

KW - Fracture

KW - Osteogenesis imperfecta

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=13644264359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13644264359&partnerID=8YFLogxK

M3 - Article

C2 - 15679068

AN - SCOPUS:13644264359

VL - 18

SP - 43

EP - 53

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 1

ER -